NASDAQ:ARVNArvinas Stock Price, Forecast & News

Arvinas' stock was trading at $44.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARVN shares have decreased by 36.6% and is now trading at $27.94.
View which stocks have been most impacted by COVID-19.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arvinas.

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Arvinas.

Arvinas Inc (NASDAQ:ARVN) announced its earnings results on Tuesday, August, 4th. The company reported ($0.65) EPS for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.06. Arvinas had a negative net margin of 182.59% and a negative return on equity of 31.68%.
View Arvinas' earnings history.

11 analysts have issued 1-year price targets for Arvinas' shares. Their forecasts range from $38.00 to $75.00. On average, they anticipate Arvinas' stock price to reach $57.10 in the next year. This suggests a possible upside of 104.4% from the stock's current price.
View analysts' price targets for Arvinas.

News headlines about ARVN stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arvinas earned a coverage optimism score of -4.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future.
View the latest news about Arvinas.

Arvinas saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 1,820,000 shares, an increase of 14.5% from the January 31st total of 1,590,000 shares. Based on an average daily volume of 354,400 shares, the short-interest ratio is currently 5.1 days. Currently, 7.9% of the company's stock are short sold.
View Arvinas' Short Interest.

Some companies that are related to Arvinas include HUTCHISON CHINA/S (HCM), Schrodinger (SDGR), Allakos (ALLK), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), FibroGen (FGEN), Legend Biotech (LEGN), HYPERA S A/S (HYPMY), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR), Arena Pharmaceuticals (ARNA), Global Blood Therapeutics (GBT), Biohaven Pharmaceutical (BHVN) and Reata Pharmaceuticals (RETA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), Crispr Therapeutics (CRSP), ImmunoGen (IMGN), Enphase Energy (ENPH), Energy Transfer LP Unit (ET), Gilead Sciences (GILD), Nabriva Therapeutics (NBRV), NVIDIA (NVDA), Opko Health (OPK) and G1 Therapeutics (GTHX).

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by a number of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.93%), Barclays PLC (0.32%), Rossmore Private Capital (0.26%), Bank of New York Mellon Corp (0.25%), California Public Employees Retirement System (0.17%) and State of Wisconsin Investment Board (0.12%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, John G Houston, Liam Ratcliffe, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am.
View institutional ownership trends for Arvinas.

ARVN stock was sold by a variety of institutional investors in the last quarter, including Algert Global LLC, Rossmore Private Capital, and Russell Investments Group Ltd.. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, and Sean A Cassidy.
View insider buying and selling activity for Arvinas.

ARVN stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Barclays PLC, Aigen Investment Management LP, Bank of New York Mellon Corp, Principal Financial Group Inc., California Public Employees Retirement System, First Trust Advisors LP, and State of Wisconsin Investment Board. Company insiders that have bought Arvinas stock in the last two years include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, Liam Ratcliffe, Sean A Cassidy, and Timothy M Shannon.
View insider buying and selling activity for Arvinas.

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARVN stock can currently be purchased for approximately $27.94.

Arvinas has a market capitalization of $1.10 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Arvinas employs 83 workers across the globe.

The official website for Arvinas is www.arvinas.com.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]